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RNA Sequencing Reveals Novel 
Transcripts from Sympathetic 
Stellate Ganglia During Cardiac 
Sympathetic Hyperactivity
Emma N. Bardsley  1, Harvey Davis  1, Olujimi A. Ajijola2, Keith J. Buckler1, Jeffrey L. Ardell2, 
Kalyanam Shivkumar  2 & David J. Paterson  1
Cardiovascular disease is the most prevalent age-related illness worldwide, causing approximately 15 
million deaths every year. Hypertension is central in determining cardiovascular risk and is a strong 
predictive indicator of morbidity and mortality; however, there remains an unmet clinical need for 
disease-modifying and prophylactic interventions. Enhanced sympathetic activity is a well-established 
contributor to the pathophysiology of hypertension, however the cellular and molecular changes 
that increase sympathetic neurotransmission are not known. The aim of this study was to identify key 
changes in the transcriptome in normotensive and spontaneously hypertensive rats. We validated 
15 of our top-scoring genes using qRT-PCR, and network and enrichment analyses suggest that 
glutamatergic signalling plays a key role in modulating Ca2+ balance within these ganglia. Additionally, 
phosphodiesterase activity was found to be altered in stellates obtained from the hypertensive rat, 
suggesting that impaired cyclic nucleotide signalling may contribute to disturbed Ca2+ homeostasis and 
sympathetic hyperactivity in hypertension. We have also confirmed the presence of these transcripts 
in human donor stellate samples, suggesting that key genes coupled to neurotransmission are 
conserved. The data described here may provide novel targets for future interventions aimed at treating 
sympathetic hyperactivity associated with cardiovascular disease and other dysautonomias.
Sympathetic hyperactivity is a key feature of human hypertension that is also seen in animal models of cardio-
vascular disease1,2. In the spontaneously hypertensive rat (SHR), a genetic-based model of hypertension, dysau-
tonomia occurs prior to increases in arterial blood pressure3–5. This neural phenotype is a powerful predictor 
of morbidity and mortality6–8. Indeed, vagal nerve stimulation9,10 and sympathetic stellectomy11 have had some 
success in the prevention of arrhythmia where neuromodulation is now being considered as an adjunct therapy12.
The sympathetic stellate ganglia (cervicothoracic ganglia) are located alongside vertebrate T1 to T3. They are 
the primary sympathetic ganglia that innervate the heart and as such, exert the greatest control over increases in 
heart rate and contractility. The precise mechanisms that underpin enhanced sympathetic nerve activity (SNA) 
in disease are unknown, however, research indicates that high intracellular Ca2+ ([Ca2+]i)2,4,13 and impaired Ca2+ 
handling linked to oxidative stress14,15 are key features in this process and predispose to dysautonomia2,4,13,16.
In the spontaneously hypertensive rat (SHR), postganglionic sympathetic neurons (PGSNs) display increased 
[Ca2+]i transients as a result of increased N-type voltage-gated Ca2+ (IcaN, Cav2.2) channel activity2,17 and 
impaired endoplasmic reticulum (ER) and mitochondrial Ca2+ handling4. Cyclic nucleotides (cNs) and their 
effectors regulate Ca2+ conductance predominantly via phosphorylation of ion channels, however, the relation-
ship between cN second messenger signalling pathways and abnormal [Ca2+]i is still poorly understood in dis-
ease2,3. Moreover, specific gene ontologies and protein-protein interactions linked to abnormal Ca2+ regulation in 
sympathetic neurons from hypertensive states is lacking.
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Here, we carried out an RNA sequencing transcriptomic analysis to identify differential gene expression in 
sympathetic neurons from normotensive and hypertensive rats. Importantly, our RNAseq results demonstrated 
significant differential expression in transcripts that regulate [Ca2+]i signalling in addition to genes that regu-
late cN signalling in disease. We validated our findings using quantitative real-time polymerase chain reaction 
(qRT-PCR) and subsequently assessed whether these genes were present in sympathetic stellate ganglia from 
human donors, in order to provide a framework for future validation and targeting.
Results
Study Design. To study the rat stellate ganglia transcriptome, we obtained RNA from four male 16-week-old 
SHR with hypertension and four male age-matched Wistar control rats. RNA extracts from these ganglia con-
tained ~8.5 ng/μL RNA. RNA integrity (RIN) was validated using an Agilent 2100 Bioanalyzer. To ensure good 
quality RNA we only used samples with RINs >8.5 for sequencing. Using the HiSeq 4000 sequencing platform, 
we generated ~345 million reads of 75-bp paired-end RNAseq data, i.e. ~22 million reads per sample. We per-
formed a comparative analysis of the stellate ganglia transcriptome between Wistar and SHR phenotypes. The 
number of animals per group (n = 4) and the sequencing parameters established were based on the recommen-
dations of the Wellcome Trust Centre for Human Genomics, in addition to those published by Conesa et al.18. 
Figure 1 illustrates our RNAseq pipeline.
Quasi-mapping and Differential Expression Analysis. Transcript level quantification was performed 
using the quasi-mapping function of the Salmon package, where inbuilt functions corrected for GC and posi-
tional bias19. These data were converted into quantitative gene level expression values, and the differential gene 
expression between the strains was calculated and normalised using DESeq220. We obtained an average num-
ber of mapped reads (74.75%) that was not significantly different between groups (Table 1). DESeq2 was used 
to generate an MA plot for visual representation of our genomic data (Supplementary Fig. 1a) and a Principal 
Component Analysis (PCA) plot with log normalisation was produced to demonstrate variation within our 
samples (Supplementary Fig. 1b)20. As confirmation of the expected neuronal phenotype, we identified that 
markers consistent with sympathetic neurons were among the most highly expressed genes in both strains (e.g. 
Figure 1. RNA Sequencing Pipeline.
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Dopamine-β hydroxylase, Dbh; and Neuropeptide Y, Npy; see Table 2). The differential expression analysis identi-
fied 776 differentially expressed genes in the stellate ganglia, where approximately 55% of genes were upregulated 
and 45% downregulated in the SHR. The top 20 differentially expressed genes are displayed (Fig. 2).
Gene Ontology Analysis. To assess the relevance of the observed differentially expressed genes, we grouped 
these genes into Gene Ontology (GO) families21 using the ClusterProfiler R package22. We identified significant 
differences between the SHR and Wistar transcriptome in the following GO categories: Molecular Function (MF) 
Sample Strain Mapping rate Number of mapped reads
Sample1 Wistar 78.66% 35509076
Sample2 Wistar 75.57% 30112270
Sample3 Wistar 78.38% 34634784
Sample4 Wistar 75.18% 33764576
Sample5 SHR 70.63% 31194868
Sample6 SHR 78.47% 25820298
Sample7 SHR 68.50% 32573670
Sample8 SHR 72.60% 34026720
Table 1. Read mapping rates via Salmon’s quasi-mapping function. Mapping rate indicates the percentage of 
assigned reads relative to the total number of reads. The numerical value for mapped reads per sample are also 
shown.
Wistar SHR
Gene Mean Counts Gene Mean Counts
Tuba1a 877116.071 Tuba1a 922096.7557
Ubb 616451.3926 Rn28s 675041.3777
Rn28s 531551.2116 Ubb 583166.9017
Tubb3 489766.6486 Tubb3 489906.3397
Dbh 365271.5768 Rn18s 307588.9061
Rn18s 314117.4054 Dbh 299093.8225
Aldoa 260208.4448 Hspa8 245512.6941
Thy1 251700.8758 Actg1 241889.488
Ndrg4 248263.1557 Aldoa 236588.5852
Hspa8 245297.6199 Ndrg4 224655.0884
Actg1 241090.67 Actb 195887.7534
Actb 227909.538 Thy1 192753.2441
Ubc 167733.1003 Npy 192441.4061
Npy 166746.7384 Hsp90ab1 167854.4376
Fth1 166495.3895 LOC310926 167425.7802
Tuba1b 166011.3638 Gapdh 166721.7809
Gapdh 164910.0889 Tuba1b 165999.6912
Uchl1 153108.9558 Uchl1 137628.8969
Hsp90ab1 151214.2007 Stmn2 134260.5427
Stmn2 139862.0444 Pkm 129310.0511
LOC310926 132381.9518 Ubc 128414.6292
Zwint 125736.4614 Cyb561 124946.1778
Pkm 122043.8767 Fth1 124938.6603
Cyb561 114908.2288 Eno1 121470.1003
Eno1 114075.9204 Fxyd6 120968.7869
Snap25 112163.485 Ppia 113541.3151
Eef1a1 111814.9377 Tubb5 112056.0616
Tubb5 111260.3167 Sncg 110216.3007
Sncg 109948.206 Zwint 109996.2104
Th 105911.6304 Eef1a1 109106.2249
Table 2. Defining the transcriptome of Wistar and SHR stellate ganglia. The table includes a list of the top 30 
genes and their respective mean counts in stellate ganglia obtained from Wistar and SHR. Genetic markers of 
sympathetic neurons are highlighted in bold. No significant difference was found for any of the sympathetic or 
neuronal markers in this list.
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and Cellular Component (CC). Semantically redundant groups were removed using the ClusterProfiler R pack-
age22. For the purpose of this study, we aimed to assess the differences in the SHR PGSN transcriptome that may be 
linked to the observed sympathetic hyperactivity and enhanced neurotransmission; therefore, we chose to focus 
our attention on the over-represented MF GO groups (at p.adj < 0.01). The most highly significant GO group 
within the MF category was identified as ‘extracellular ligand-gated ion channel activity’ (Fig. 3; GO:0005230; 
p.adj = 3 × 10−5). The other significantly over-represented GO groups in the SHR stellate ganglion include (in 
order of significance): ‘phosphoric ester hydrolase activity’ (Fig. 3; GO:0042578; p.adj = 1.72 × 10−4), ‘organic acid 
binding’ (Supplementary Table 1; GO:0043177; p.adj = 2.90 × 10−3), ‘glutamate receptor activity’ (Supplementary 
Table 1; GO:0008066; p.adj = 2.90 × 10−3), ‘gated channel activity’ (Supplementary Table 1; GO:0022836; p.
adj = 3.59 × 10−3) and ‘carboxylic acid binding’ (Supplementary Table 1; GO:0031406; p.adj = 4.93 × 10−3). Of 
the over-represented MF GO groups, we found significant overlap between the genes identified in ‘extracellular 
Figure 2. Overview of the differentially expressed genes in the stellate ganglia. The Venn diagram represents 
the total number of upregulated gene transcripts (353) and downregulated transcripts (423) in the SHR stellate 
ganglia, identified by DESeq2 analysis (a). The top differentially expressed transcriptomic changes between 
Wistar and SHR sympathetic stellate ganglia are listed; where green and blue represent up- and downregulated 
genes respectively (b). The heat-map represents the expression levels of differentially expressed genes in Wistar 
and SHR stellate ganglia. The colour legend indicates similarity of gene expression between samples. The colour 
gradients of samples indicate the inter-sample similarity of transcript expression for a particular gene. The 
dendrogram depicts overall similarity of the samples within this geneset, highlighting the distinction between 
strains as well as between samples within strains (c).
www.nature.com/scientificreports/
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ligand-gated ion channel activity’ (GO:0005230) ‘glutamate receptor activity’ (GO:0008066) and ‘gated chan-
nel activity’ (GO:0022836) as these GO groups form sub-categories of the parent GO group ‘ligand-gated ion 
channel activity’ (GO:0015276). In addition, ‘organic acid binding’ (GO:0043177) and ‘carboxylic acid binding’ 
(GO:0031406) are sub-branches of the larger parent group ‘small molecule binding’ (GO:0036094). Full lists of 
the significantly different MF and CC GO groups identified in SHR PGSNs are included in the supplementary 
data (Supplementary Tables 1, 2). Importantly, the differentially expressed transcripts within these GO groups 
may be linked to sympathetic dysfunction observed in the SHR model. There were no significantly different GO 
groups in the Biological Process (BP) category between Wistar and SHR.
Differential Expression of Extracellular Ligand-Gated Ion Channel Genes: Confirmation by 
qRT-PCR. We obtained four independent Wistar and SHR RNA stellate ganglia to investigate whether we 
could replicate the RNAseq differential gene expression using qRT-PCR. In the 15 selected genes, we obtained 
similar trends using qRT-PCR as that observed in the RNAseq data; although due to variation within sam-
ples, only 4:15 genes reached significance (Fig. 4, unpaired two-tailed students t-test; Wistar vs. SHR). These 
included Chrnb4 (Cholinergic Receptor Nicotinic β4 Subunit), Gria1 (Glutamate Ionotropic Receptor AMPA 
Type Subunit 1), Grik1 (Glutamate Ionotropic Receptor Kainate Type Subunit 1) and Grin2b (Glutamate 
Ionotropic Receptor NMDA Type Subunit 2B).
Extracellular Ligand-Gated Ion Channel Genes Are Expressed in Human Sympathetic Stellate 
Ganglia. To assess whether these genes are conserved in other species and have potential relevance for human 
sympathetic activity, we validated the expression of these genes in ganglia obtained from human donors. Given 
the limited availability of human tissue from patients, it was not possible to assess the role of these genes in human 
disease itself. Importantly, however, we detected the presence of glutamate (AMPA, NMDA and Kainate) and 
GABA receptor subunits which have not been previously identified within the human sympathetic stellate ganglia 
(Fig. 4). We also identified the presence of purinergic, glycinergic and serotonergic receptors.
Differential Expression of Phosphoric Ester Hydrolase Activity Genes. The ‘phosphoric ester 
hydrolase activity’ (GO:0042578) GO group was found to contain the highest number of differentially expressed 
Figure 3. Gene Ontology: Molecular Function Category. The top two over-represented molecular function 
(MF) gene ontology (GO) groups include ‘extracellular ligand-gated ion channel activity’ (GO:0005230) and 
‘phosphoric ester hydrolase activity’ (GO:0042578; a). Venn diagrams depict the upregulated genes (green) and 
downregulated genes (blue) in each GO group (b,c; respectively). All other over-represented GO groups are 
included in the supplementary dataset.
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genes in the MF category. We identified 13 upregulated genes including Pde6b and 20 downregulated mRNA 
transcripts including Pde11a and Pde2a (Figs 3 and 5). The expression of 270 genes in this group was unchanged. 
Within this family, we identified that most of the affected transcripts were those encoding phosphatase enzymes.
KEGG Functional Enrichment Pathways are Impaired in SHR Stellate Ganglion. Using the 
ClusterProfiler R package22, we performed a Kyoto Encyclopedia of Genes and Genome (KEGG)23–25 path-
way enrichment analysis, that links the observed differences within the SHR PGSN transcriptome to relevant 
intracellular signalling pathways. We analysed the relevance of the differentially expressed genes by perform-
ing a functional enrichment KEGG analysis that identified ‘Circadian Entrainment’ (rno04713; p.adj = 0.004); 
‘Dopaminergic Synapse’ (rno04728; p.adj = 0.004); ‘Retrograde Endocannabinoid Signalling’ rno04723; 
p.adj = 0.0196); ‘Glutamatergic Synapse’ (rno04724; p.adj = 0.0259) and ‘Neuroactive Ligand-receptor 
Interaction’ (rno04724; p.adj = 0.0259) as the most over-represented pathways in the hypertensive strain (Fig. 6, 
Supplementary Table 3).
Importantly, many of the same genes were represented in each of these groups, therefore we combined the 
KEGG signalling pathways (Circadian Entrainment, Dopaminergic Synapse and Glutamatergic Synapse) to iden-
tify the possible involvement of these transcriptomic changes on intracellular signalling (Fig. 6b,c). The KEGG 
enrichment pathway observations indicate that RNA transcripts associated with glutamate signalling are dif-
ferentially expressed within SHR cardiac PGSNs. Within these KEGG groups, genes associated with glutamate 
signalling are coupled to [Ca2+]i directly, where differences in subunit composition of glutamate-activated ion 
channels affect Ca2+ permeability. Moreover, cyclic nucleotide generation and activation of their effectors are 
Figure 4. Extracellular Ligand-Gated Ion Channel Activity GO Group (GO:0005230). The differentially 
expressed genes in the MF GO group ‘extracellular ligand-gated ion channel activity’ (GO:0005230) are listed, 
where green and blue represent up- and downregulated genes respectively (a). The presence of these genes was 
validated using qRT-PCR and the ΔΔCT comparative method was applied for analysis (SHR/Wistar); with 
β2 microglobulin (B2m) selected as the housekeeping gene for comparison as there was no difference in B2m 
expression between strains in the RNAseq dataset. Log2 fold change of the differentially expressed genes in SHR 
stellates as identified by RNAseq are represented in red (b). Log2 fold change ± SEM of qRT-PCR SHR data are 
also depicted (blue; b) relative to Wistar. Significance is indicated above the relevant bars. The RNAseq trends 
for up- or downregulation of each gene was confirmed with qRT-PCR; however, only Chrnb4 (p < 0.05), Gria1 
(p < 0.001), Grik1 (p < 0.05) and Grin2b (p < 0.05) were significantly different to the expression levels measured 
in Wistar samples. The presence of these genes was confirmed in human stellate ganglia samples (c). To quantify 
mRNA expression in human stellate samples, data were normalised to the housekeeping gene B2m and the 
ΔCT method was applied for analysis.
www.nature.com/scientificreports/
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thought to influence the activity of these channels (Fig. 6b,c). The interaction between glutamate signalling and 
cyclic nucleotides within the peripheral nervous system has not been previously described.
Discussion
We have used RNAseq to identify alterations in the transcriptome of the stellate ganglion between SHR and 
Wistar rats, in order to establish lead genetic candidates that may be linked to sympathetic hyperactivity in this 
hypertensive model26–30.
Here we report several novel findings. First, we observed differential expression in the GO group encoding 
extracellular ligand-gated ion channels that are linked to intracellular Ca2+ regulation. These changes were con-
firmed by qRT-PCR. Secondly, we provide evidence for the impaired expression for a family of genes that encode 
PDEs and phosphatase activity in hypertension. Altered transcription of PDEs and associated phosphatases that 
regulate PDE activity may be coupled to the dysregulation of cyclic nucleotide signalling, which is impaired in 
neurogenic hypertension2. Finally, to provide physiological context, we show that key differentially expressed 
genes are conserved and present in human stellate ganglia.
We observed high levels of transcripts involved in pathways governing adrenergic synthesis (e.g. Dbh, Th), 
neurotransmission (e.g. Snap25) and reuptake (e.g. Slc6a2), corroborating similar recently published profiles of 
stellate neurons31–33. We found that the highest number of differentially expressed genes between Wistar and 
SHR stellate ganglia within the molecular function (MF) gene ontology (GO) category, were associated with the 
‘extracellular ligand-gated ion channel’ (GO:0005230) and the ‘phosphoric ester hydrolase activity’ (GO:0042578) 
superfamilies. In particular, our data highlighted significant differences in the mRNA transcript expression levels 
of several glutamate-activated ion channel subunits including: upregulation of the NMDA receptor (R) NR2 
Figure 5. Phosphoric Ester Hydrolase Activity GO Group (GO:0042578). The differentially expressed genes in 
the MF GO group ‘phosphoric ester hydrolase activity’ (GO:0042578) are listed, where green and blue represent 
up- and downregulated genes respectively (a). Log2 fold change of the differentially expressed genes of interest 
in SHR relative to Wistar as identified by RNAseq (b).
www.nature.com/scientificreports/
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subunit (Grin2b) and AMPA GluA3 subunits (Gria3); as well as downregulation of AMPA GluA1 and GluA2 
subunits (Gria1, 2) and Kainate 1 and 2 R subunits (Grik1, 2 respectively), supporting previous evidence for 
the role of amino acids in regulating cardiac-sympathetic activity34–37. Within the ‘extracellular ligand-gated ion 
channel’ GO Group, we also identified significant changes in the transcript expression levels of purinergic Rs 
(P2rx3, 4, 6) and GABAA R subunits (Gabra1, Gabra2). We also observed a significant downregulation of the 
ionotropic serotonin type 3 R subunits (Htr3a, Htr3b), nicotinic acetylcholine R β4 subunit (Chrnb4) and the 
chloride (Cl−)-permeable glycine channel β subunit (Glrb). Our RNAseq data provides an accurate prediction 
of the differential expression of these genes, as the trend for up- or downregulation was confirmed by qRT-PCR 
(Fig. 4). Moreover, using qRT-PCR we confirmed the presence of these genes within human male donor PGSNs 
Figure 6. KEGG Enrichment Pathways in SHR versus Wistar Stellate Ganglion. We identified 3 KEGG 
functional enrichment pathways that are particularly relevant to post-synaptic postganglionic signalling (a). 
The highest over-represented group was ‘Circadian Entrainment’ (rno04713; p. adj = 4.24 × 10−3) followed 
by ‘Dopaminergic Synapse’ (rno04728; p. adj = 4.24 × 10−3) and ‘Glutamatergic Synapse’ (rno04724; p. 
adj = 2.59 × 10−2). The Venn Diagram depicts the upregulated genes (green) and downregulated genes (blue) 
and highlights the overlap between each of the respective over-represented KEGG groups (b). Other over-
represented KEGG groups are included in the supplementary data. In (c), we show an integrated KEGG 
enrichment diagram, combining signalling pathways from the over-represented KEGG pathways ‘Circadian 
entrainment’, ‘Dopaminergic synapse’ and ‘Glutamatergic synapse’. Here we highlight the possible involvement 
of these transcriptomic changes on intracellular signalling. This figure is primarily based on the supplied 
rno04713 KEGG diagram.
www.nature.com/scientificreports/
9SCIENTIfIC REPORTS |  (2018) 8:8633  | DOI:10.1038/s41598-018-26651-7
(Fig. 4). Importantly, differential expression of ligand-gated ion channel subunits may have implications for ion 
permeability. The expression of these as-yet unreported ion channels on human sympathetic nerves has clear 
clinical relevance, as it may offer new targets for interventions aimed at modulating neurotransmission as well as 
considerations regarding the side effect profiles of current therapeutics.
We also analysed the relevance of differentially expressed genes by performing a functional enrichment 
KEGG analysis. This identified ‘Circadian Entrainment’, ‘Dopaminergic Synapse’, ‘Retrograde Endocannabinoid 
Signalling’, ‘Glutamatergic Synapse’ and ‘Neuroactive ligand-receptor Interaction’ as the most over-represented 
pathways in the hypertensive strain (Fig. 6). Within these KEGG enrichment pathways, the genes associated with 
glutamate signalling were the most heavily over-represented genes, supporting previous evidence that amino 
acids may play a role in regulating sympathetic activity in healthy physiological conditions34,36,37. The NMDAR 
NR2 subunit (Grin2b) that was found to be upregulated in SHR ganglia, is the binding site for glutamate and 
plays a direct role in regulating the electrophysiological properties of the channel38–40. Moreover, decreases in the 
AMPA subunit GluA2 (Gria2) mRNA expression may be associated with increased Ca2+ permeability. Indeed, 
in CA1 pyramidal neurons, increased cAMP and PKA signalling shift GluA2/3-containing AMPARs to a more 
conductive state41,42. Whether impaired cN signalling within SHR PGSNs affects AMPA R conductance and con-
tributes to the observed Ca2+ dysfunction within sympathetic stellate neurons remains to be established.
Within the over-represented KEGG groups we identified several differentially expressed transcripts indicat-
ing that cGMP-PKG signalling may be downregulated. We have previously identified an impairment in cyclic 
nucleotide (cN) signalling linked to dysregulated [Ca2+]i in hypertensive states2,3 and have demonstrated that 
enhancing cGMP signalling rectifies this feature2. We observed that the transcripts encoding the soluble guanylyl 
cyclase 1 soluble subunit α (Gucy1a3) and the cGMP-dependent Protein Kinase (PKG) type II subunit (Prkg2) 
are significantly downregulated in SHR ganglia. Importantly, we identified that the ‘phosphoric ester hydrolase 
activity’ (GO:0042578) was also significantly over-represented within the MF category. Within this GO group, 
we identified 33 significantly differentially expressed transcripts, including downregulation of Pde11a and Pde2a 
transcripts and upregulation of Pde6b (Fig. 5) supporting previous evidence that PDE dysregulation may play a 
role in cardiovascular diseases13,16,43–46. Recently, it was demonstrated that 1% of the Swedish population carry 
a loss-of-function mutation in PDE11a that is directly linked to hypertension, obesity and ischaemic stroke47. 
Moreover, a single nucleotide polymorphism (rs197163010) has been identified in PDE2a in the SHR/ola strain 
and reported in the NCBI dbSNP database48. Importantly, a number of other differentially expressed genes within 
this group also relates to the regulation of cell function through protein phosphorylation, including protein tyros-
ine and phosphoserine phosphatases that regulate protein kinase effector activity. A full overview of the differen-
tially expressed transcripts are displayed in Fig. 5; however, it is pertinent to note that cN activity is dependent on 
PDE activity that is closely localised within specific subcellular microdomains49.
Several genes that we identified within these pathways have been previously associated with hypertension and 
CVDs. These include the class III metabotropic glutamate receptor 7 (Grm7)50,51, G-protein β3 subunit (Gnb3)52–55  
and the voltage gated L-type Ca2+ Cannel α subunit (Cacna1c)56,57. Of particular relevance to this study is the 
finding that Protein Kinase A regulatory subunit 1a (Prkar1a) is downregulated in these cell types. Prkar1a tran-
scription is integral for normal development of peripheral neurons including axonal sorting, myelination and 
proliferation of neurons58. Additional support for the importance of Prkar1a in peripheral neurons is found in 
patients with the inherited Carney Complex (CNC) syndrome59,60. Notably, patients with global loss-of-function 
mutations in Prkar1a develop peripheral nerve tumours and display a wide range of cardiovascular comorbidities 
that are often fatal, including dysregulated maintenance of blood pressure, cardiomyopathies and arrhythmia60. 
Indeed, in one study approximately 60% of CNC patients died of cardiovascular complications59.
Limitations. In this study, we carried out a hypothesis neutral, non-biased approach to sequencing the tran-
scriptome of sympathetic stellate neurons of SHR and normotensive Wistar rats. There are several limitations to 
this approach. First, the stellate ganglion comprises a heterogeneous population of cell types. This was apparent in 
the analysis, as we identified several markers of fibroblasts and astrocytes including vimentin and glial fibrillary 
acidic protein (GFAP) respectively, however; a high number of identified transcripts were of neuronal phenotype. 
Further studies to fully uncover the transcriptome of PGSNs require single cell RNAseq or confirmation of RNA 
transcripts in single PGSNs, using techniques such as in situ hybridisation for nucleic acids. Secondly, we used 
stellates obtained from male rats. While there is a plethora of data regarding the sex differences in hypertension 
and CVD incidence61, in this study we focussed on investigating the transcriptome of the male rat stellate ganglia, 
given that the prevalence for hypertension and CVD is significantly higher in males compared with premenopau-
sal women61. Thirdly, given the low concentration of RNA in our stellate samples, we chose to amplify our samples 
during the library preparation using the SMARTer amplification protocol. We are aware that low level transcripts 
may be under-represented in the amplification process and in our dataset. Moreover, since we sequenced the 
transcriptome from rats with established hypertension, the transcriptomic changes that we identified may occur 
as compensatory rather than causative factors. Finally, our gene profiling and ontology analyses are enabled, yet 
limited, by the GO groups and KEGG enrichment pathways currently available.
Notwithstanding these limitations, RNAseq transcriptomics has revealed differential gene expression profiles 
in PGSNs obtained from SHR with established hypertension and normotensive Wistar rats. Leading transcripts 
were also present in human stellate ganglia. Taken together, these genes provide a starting framework to further 
investigate their role in sympathetic hyperactivity and other diseases associated with autonomic dysfunction.
Methods
Animals. 16-week old male SHRs with established hypertension and age-matched normotensive Wistar con-
trol rats were obtained from Envigo, UK. At 16-weeks, it is well-established that SHR display hypertension and 
sympathetic hyperactivity4,30,62–66. In this study, we used the Wistar rat strain as the normotensive control, given 
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that Wistar rats are the progenitor strain for WKY and the two strains display similar hemodynamic profiles at all 
ages as measured using multiple methods4,66–72. We have previously shown that neither Wistar nor WKY display 
a sympathetic Ca2+ phenotype (unlike the SHR)13 making the Wistar a suitable control in this study73. All rats 
were housed in standard plastic cages and artificial lighting was fixed to a natural 12-hour light/dark cycle. Food 
and water were available ad libitum. All experiments were performed in accordance with the UK Home Office 
Animal Scientific Procedures Act 1986 (ASPA) and approved by the University of Oxford (PPL 30/3131; David 
J. Paterson).
RNA Extraction from Sympathetic Cardiac Ganglia. Right and left postganglionic sympathetic 
stellate neurons were dissected from 16-week-old male SHR and age-matched male Wistar rats. Right stellate 
ganglia were removed for RNA sequencing and the left stellate ganglia were used for matched qRT-PCR exper-
iments. Rats were anaesthetised in an induction chamber (3–5% isoflurane) and humanely killed by a Home 
Office approved Schedule 1 method: overdose of pentobarbital (Euthatal, 200 mg/mL) and exsanguination. The 
stellate ganglia were placed in Hanks Buffered Saline Solution without Ca2+ and Mg2+. For clinical samples, 
human ganglia (n = 3 patients, two left and two right stellates) were extracted at UCLA and shipped on dry ice in 
RNAlater® RNA Stabilization Solution (ThermoFisher). Rat and human ganglia were cleaned and de-sheathed 
and each sample contained RNA from one stellate. Briefly, stellate ganglia were transferred immediately to RLT 
lysis buffer (Qiagen) with β-mercaptoethanol (1%). Stellates were finely chopped and carefully triturated with 
fire-blown Pasteur pipettes until adequately digested. An equal volume of ethanol (70%) was added to each 
sample and vortexed. Rat RNA was extracted using an RNeasy Mini RNA Extraction Kit (Qiagen) and human 
RNA was extracted using an RNeasy Maxi RNA Extraction Kit (Qiagen) in accordance with the manufacturer’s 
instructions. RNA samples were divided and aliquoted for qRT-PCR and quality control experiments before 
snap freezing in liquid nitrogen and storage at −80 °C. The RNA quality and integrity from each sample, was 
confirmed using a 2100 Bioanalyzer Instrument with an RNA 6000 pico kit (Agilent). Rat samples with an RNA 
integrity number (RIN) less than 8.5 were discarded. Due to difficulties with fast shipping of human samples we 
accepted human RNA samples with RINs above 5.7. RNA concentrations were determined using a Qubit RNA 
High Sensitivity Assay Kit (Molecular Probes, Life Technologies) and a Qubit® 2.0 Fluorometer (Invitrogen, 
Life Technologies). Regarding the extraction of human ganglia; all methods were carried out in accordance with 
relevant guidelines and regulations. The human study was approved by an institutional committee, the UCLA 
Institutional review board, approval # 12-000701, and informed consent was obtained from all subjects.
cDNA library preparation for RNA Sequencing. 4 samples containing total RNA extracted from the right 
sympathetic stellate ganglion of 16-week-old male SHR (n = 4) and age-matched Wistar (n = 4) were sent to the 
High-Throughput Genomics Group at the Wellcome Trust Centre for Human Genetics (WTCHG) for RNAseq 
library construction and sequencing using an Illumina HiSeq 4000 (Illumina, Inc., San Diego, USA). The sequencing 
libraries were amplified using a SMARTer (first strand synthesis) amplification protocol, due to the low initial RNA 
concentrations obtained from a single stellate, and prepared for paired-end sequencing (2 × 75 bp). Each sample was 
sequenced on two separate lanes to minimise technical error and to increase the sequencing depth (~15–25 million 
reads per lane). Samples were randomized and blinded to the experimenter. The sequencing parameters established, 
were based on recommendations from WTCHG and those published by Conesa et al.18.
Quasi-mapping. Transcripts were quantified via the Salmon (version 0.8.2) package using the transcriptome-based 
quasi-mapping mode19. The following commands were used during quasi-mapping in accordance with the Salmon 
guidelines: salmon quant –I transcripts_index -l ISR a −1/SampleX_lane1_mate1.fastq.gz/SampleX_lane2_mate1.
fastq.gz −2/SampleX_lane1_mate2.fastq.gz/SampleX_lane2_mate2.fastq.gz -o Sample1–dumpEq–posBias–gcBias –
writeUnmappedNames. The transcript index used during quasi-mapping was derived from the UCSC refseq rn6.0 
mRNA library available at the following link: http://hgdownload.soe.ucsc.edu/goldenPath/rn6/bigZips/refMrna.fa.gz.
Data files were assigned alternative names to blind the experimenter during the relevant stages of the 
quasi-mapping analysis.
Differential Expression Analysis. Once each sample was quantified, the data were imported into R and 
summarised to a gene-level using the ‘Tximport’ function (v1.4.0)74. Gene level differential expression analysis 
between Wistar and SHR samples was performed using the 'DESeq2' command in DESeq2 (version 1.16.1)20. 
Significance for differential expression was accepted at the Benjamini-Hochberg adjusted p < 0.05 level. The 
‘LFCshrink’ function was used to shrink log fold changes after analysis as per the DESeq2 vignette20.
Gene ontology and KEGG analysis. Gene ontology (GO) and KEGG over-representation tests were 
performed using ClusterProfiler (Version 3.4.4) with ‘EnrichGO’ and ‘EnrichKEGG’ functions respectively22. 
The differentially expressed gene input was taken at the Benjamini-Hochberg adjusted p < 0.05 level. Significant 
groups were subsequently determined using Benjamini-Hochberg correction and cut-off levels of p < 0.01 and 
q < 0.05 were enforced. Redundancy amongst GO terms was removed using the ClusterProfiler simplify com-
mand, where the adjusted p-value was used as the deciding variable, with a cut-off value of 0.7. The ClusterProfiler 
‘Enrichmap’ function was used to generate KEGG enrichment maps23–25. We subsequently generated an inte-
grated KEGG enrichment diagram by combining signalling pathways from the over-represented KEGG pathways 
‘Circadian entrainment’, ‘Dopaminergic synapse’ and ‘Glutamatergic synapse’.
cDNA Library Preparation for qRT-PCR. We used 50 ng stellate RNA for constructing the qRT-PCR 
cDNA libraries. For rat PGSN RNA, the SuperScriptTM III VILOTM cDNA synthesis protocol was followed accord-
ing to manufacturer’s instructions. Briefly, rat RNA samples (50 ng) were added to the III VILO reaction mix, 
SuperScriptTM enzyme mix and nuclease-free H2O. The samples were vortexed and incubated in a thermocycler 
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(GStorm) at 25 °C (10 mins), 42 °C (60 mins), 80 °C (5 mins). For human PGSN RNA, the SuperScriptTM IV 
VILOTM cDNA synthesis protocol was followed according to manufacturer’s instructions (ThermoFisher). Briefly, 
human RNA samples (50 ng) were added to ezDNAse buffer, exDNAse enzyme and nuclease-free H2O. The sam-
ples were mixed and incubated (37 °C, 2 min). SuperScriptTM IV VILOTM master mix (or for control experiments 
SuperScriptTM IV VILOTM no reverse transcriptase) was added to each sample with nuclease-free H2O. The sam-
ples were mixed and incubated in a thermocycler (GStorm, GS4822) at 25 °C (10 mins), 50 °C (10 mins), 85 °C 
(5 mins). Concentrations of cDNA in each sample and the 260/280 ratios were calculated (NanoDrop Lite) to 
detect the presence of contaminants. Samples with an abnormal 260/280 ratio (<1.7 and >1.95) were discarded. 
Samples were aliquoted and frozen at −80 °C for long-term storage or kept at 4 °C for immediate use.
Two-Step Quantitative Real-Time PCR. qRT-PCR was used to confirm the presence of the follow-
ing mRNA transcripts in the PGSN cDNA libraries: Chrnb4 (Rn00583822_m1, Hs00609523_m1); Gabra1 
(Rn00788315_M1, Hs00971228_m1); Gabra2 (Rn01413643_m1, Hs00168069_m1); Glrb (Rn00583966_M1, 
Hs00923871_m1); Gria1 (Rn00709588_m1, Hs00181348_m1); Gria2 (Rn00568514_M1 Hs00181331_m1); Gria3 
(Rn00583547_m1, Hs01557466_m1); Grik1 (Rn01458414_M1, Hs00543710_m1); Grik2 (Rn00570853_m1, 
Hs00222637_m1); Grin2b (Rn00680474_M1, Hs01002012_m1); Htr3a (Rn00667026_m1, Hs00168375_m1); 
Htr3b (Rn00573408_M1, Hs01573423_m1); P2rx3 (Rn00579301_m1, Hs01125554_m1); P2rx4 (Rn00580949_
m1, Hs00902156_g1); P2rx6 (Rn00562354_m1, Hs01003997_m1). The following controls were selected: 
beta-2-microglobulin (B2m; Rn00560865_m1, Hs00187842_m1; rat, human), glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh; Rn99999916_s1, Hs02786624_g1; rat, human). TaqMan® Gene Expression Master Mix 
(ThermoFisher) was added to each cDNA sample in addition to the selected primer conjugated to a FAM dye and 
nuclease-free H2O. cDNA samples or no reverse transcriptase controls were diluted 1:20 for optimal PCR reac-
tions. A 96-well plate with 20 μL samples (3 replicates) were run on a real-time quantitative PCR thermocycler 
(ABI, PRISM). Temperatures were held at 50 °C (2 min) and 95 °C (10 min) before thermal cycling (40 cycles) 
under the following conditions 95 °C (15 s), 60 °C (1 min). Data displayed in the results section depicts gene 
counts normalised to B2m; however, each primer was analysed against two housekeeping genes, B2m and Gapdh 
for validation and accuracy of qRT-PCR data. The relative amount of each transcript was calculated using the 
comparative (CT) method (∆∆ CT, rat; ∆ CT, human)75.
Statistical Analysis. qRT-PCR data were analysed using GraphPad Prism software (v7). When the data 
passed normality tests, an unpaired Student’s t-Test was used. When the data were not normally distributed, 
nonparametric tests were used with the specific statistical test reported in the figure legend. All qRT-PCR data 
are expressed as Log2 fold change ± SEM. Statistical significance was accepted at p < 0.05, unless otherwise 
described. For details of quality control and further methodology, please refer to76. 
Data availability. Our RNA sequencing (RNAseq) raw FastQ files are deposited in the NCBI short reads 
archive under SRA number SRP132271 (NCBI Short Read Archive) and our quasi-mapped data will be available 
under Gene Expression Omnibus (GEO) accession number (GSE110197).
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